Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines
- PMID: 8087191
- DOI: 10.1111/j.1399-3038.1994.tb00228.x
Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines
Abstract
The role of aluminium for IgG and IgE responses to pertussis toxin (PT), as well as for side effects, was investigated in 49 children with known atopy status. Primary immunization had been given with an adsorbed monocomponent or an adsorbed two-component acellular pertussis vaccine. The children were then randomized to receive a booster immunization with either aluminium-adsorbed or non-adsorbed, whole cell, pertussis vaccine. Both vaccines induced good IgG responses with the adsorbed vaccine giving higher post-booster levels (p < 0.05). The adsorbed vaccine was, however, associated with more local side effects (p < 0.05) and tended to induce higher PT-IgE responses than the non-adsorbed vaccine. Furthermore, individuals who had received the two-component vaccine as primary immunization had higher PT-IgE responses after the booster, compared with individuals initially receiving the monocomponent vaccine (p = 0.041). No correlation between PT-IgE and PT-IgG levels was seen in any of the groups. Total serum IgE levels correlated to PT IgE levels, particularly in children with atopy (r = 0.950, p < 0.001). The addition of aluminium to the pertussis vaccine, was, thus, associated with a stronger IgG antibody response, but tended also to induce a stronger IgE antibody response. The correlation between total IgE and PT-IgE, which was most prominent in children with atopy, indicates that the role of immunization for the development of allergy merits further studies.
Similar articles
-
Immunoglobulin E and G responses to pertussis toxin in children immunised with adsorbed and non-adsorbed whole cell pertussis vaccines.Vaccine. 1997 Oct;15(14):1558-61. doi: 10.1016/s0264-410x(97)00067-4. Vaccine. 1997. PMID: 9330468
-
Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization.Eur J Pediatr. 1999 Dec;158(12):989-94. doi: 10.1007/s004310051264. Eur J Pediatr. 1999. PMID: 10592076
-
Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.Clin Exp Immunol. 2000 Aug;121(2):193-200. doi: 10.1046/j.1365-2249.2000.01306.x. Clin Exp Immunol. 2000. PMID: 10931131 Free PMC article.
-
[The immunological basis of the administration of DTP-polio vaccine].Verh K Acad Geneeskd Belg. 2000;62(4):245-67. Verh K Acad Geneeskd Belg. 2000. PMID: 11004905 Review. Dutch.
-
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.Vaccine. 2013 Oct 25;31(45):5178-91. doi: 10.1016/j.vaccine.2013.08.034. Epub 2013 Aug 28. Vaccine. 2013. PMID: 23994021 Review.
Cited by
-
Vaccination and allergic disease: a birth cohort study.Am J Public Health. 2004 Jun;94(6):985-9. doi: 10.2105/ajph.94.6.985. Am J Public Health. 2004. PMID: 15249303 Free PMC article.
-
Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model.Clin Diagn Lab Immunol. 2005 Mar;12(3):409-17. doi: 10.1128/CDLI.12.3.409-417.2005. Clin Diagn Lab Immunol. 2005. PMID: 15753254 Free PMC article.
-
Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.Drugs. 2005;65(10):1367-89. doi: 10.2165/00003495-200565100-00005. Drugs. 2005. PMID: 15977969 Review.
-
Intranasal Immunization with Nasal Immuno-Inducible Sequence-Fused Antigens Elicits Antigen-Specific Antibody Production.Int J Mol Sci. 2024 Nov 28;25(23):12828. doi: 10.3390/ijms252312828. Int J Mol Sci. 2024. PMID: 39684539 Free PMC article.
-
Identification and In Silico Characterization of a Conserved Peptide on Influenza Hemagglutinin Protein: A New Potential Antigen for Universal Influenza Vaccine Development.Nanomaterials (Basel). 2023 Oct 20;13(20):2796. doi: 10.3390/nano13202796. Nanomaterials (Basel). 2023. PMID: 37887946 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources